Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 11/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938270 | 0.87 | CCR9 (0.68) | CCR9NPC1GAARAB9ASERPINE1 | |
| SCHEMBL14034607 | 0.87 | CCR9 (0.50) | CCR9SERPINE1CCR2 | |
| SCHEMBL11938271 | 0.84 | CCR9 (0.45) | CCR9SERPINE1CCR2GRM5 | |
| SCHEMBL11937175 | 0.81 | CCR9 (0.55) | CCR9SERPINE1CCR2 | |
| SCHEMBL344320 | 0.80 | CCR9 (0.79) | CCR9CCR2 | |
| SCHEMBL11938267 | 0.80 | CCR9 (0.55) | CCR9SERPINE1CCR2 | |
| SCHEMBL11936670 | 0.78 | CCR9 (0.48) | CCR9SERPINE1CCR2 | |
| SCHEMBL15906618 | 0.78 | CCR9 (0.61) | CCR9NPC1GAARAB9AKMT2A | |
| SCHEMBL11937067 | 0.78 | CCR9 (0.57) | CCR9SERPINE1CCR2 | |
| SCHEMBL10284624 | 0.77 | CCR9 (0.51) | CCR9SERPINE1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110021523-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090270616-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080293717-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270616-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885NPC1 1062/4885GAA 2519/4885 |
| US-20110021523-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885NPC1 1062/4885GAA 2519/4885 |
| US-20080293717-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885NPC1 1062/4885GAA 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.